Is HALO or IKT more undervalued in 2026?

CirclFi compares Halozyme Therapeutics, Inc. (HALO) and Inhibikase Therapeutics, Inc. (IKT) using 13 institutional-grade valuation models. HALO has a Quality of Company score of 10.0/10 while IKT scores 4.4/10.

Which is a better buy — HALO or IKT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HALO and IKT valuations compare?

HALO at $66.54 and IKT at $1.75 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HALO vs IKT Valuation Comparison 2026 — Intrinsic Value Analysis

HALO

Biological Products, (No Diagnostic Substances)

Halozyme Therapeutics, Inc.

Quality

10.0

out of 10

Value Trap

LOW

Price

$66.54

Last close

Models

12/13

Active

IKT

Biological Products, (No Diagnostic Substances)

Inhibikase Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$1.75

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	HALO Fair Value	HALO Upside	IKT Fair Value	IKT Upside
Bayesian DCF	Intrinsic	$75.35	+13.2%	$0.66	-62.4%
Earnings Power Value	Intrinsic	$23.07	-65.3%	$0.34	-82.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HALO vs IKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HALO vs IKT — Which Stock Is More Undervalued?

HALO scores higher with a 10.0/10 quality rating vs IKT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Halozyme Therapeutics, Inc. (HALO) and Inhibikase Therapeutics, Inc. (IKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HALO currently trades at $66.54 with a QOC of 10.0/10, while IKT trades at $1.75 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).